Stay updated on LN-145 + Pembrolizumab in Transitional Cell Cancer Clinical Trial
Sign up to get notified when there's something new on the LN-145 + Pembrolizumab in Transitional Cell Cancer Clinical Trial page.

Latest updates to the LN-145 + Pembrolizumab in Transitional Cell Cancer Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedThe page revision label was updated from v3.6.5 to v3.6.6. This reflects a deployment of updates to the page template or metadata without changes to the study data.SummaryDifference0.1%

- Check17 days agoNo Change Detected
- Check24 days agoNo Change Detected
- Check31 days agoChange DetectedPage revision updated from v3.6.4 to v3.6.5, indicating a minor update to the page template. This does not appear to modify any study details or eligibility information.SummaryDifference0.1%

- Check45 days agoChange DetectedRevision: v3.6.4 is now displayed on the page, replacing v3.6.3. This indicates a minor update to the page template or underlying content management system.SummaryDifference0.1%

- Check66 days agoChange DetectedRevision: v3.6.3 is now displayed on the page, replacing the previous v3.6.2. This reflects a minor update to the page’s revision tag without changes to the study content.SummaryDifference0.1%

- Check73 days agoChange DetectedThe page's revision tag was updated from v3.6.0 to v3.6.2, indicating a newer version of the page used for maintenance. This update does not modify visible content.SummaryDifference0.1%

- Check81 days agoChange DetectedThe page loses several regulatory and documentation labels, including FDA-regulated status and IPD-related terms, along with associated descriptors, which changes how regulatory context and study documents are surfaced.SummaryDifference19%

Stay in the know with updates to LN-145 + Pembrolizumab in Transitional Cell Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the LN-145 + Pembrolizumab in Transitional Cell Cancer Clinical Trial page.